Republic of Korea-based Celltrion has won a court decision that declared patents on Roche’s Herceptin invalid in Japan.
Asian news media are reporting that Republic of Korea—based Celltrion has won a court decision that declared patents on Roche’s Herceptin invalid in Japan. The decision, reports Business News Korea’s Pulse, clears the way for Celltrion to market its trastuzumab biosimilar, Herzuma, for breast cancer in Japan.
Celltrion and its Japanese distribution partner Nippon Kayaku launched the biosimilar in the Japanese market in August 2018, but only for the indications of HER2-positive gastric cancers, for which it was approved by Japan’s Ministry of Health. Korea Biomedical Review indicated that Celltrion will now seek an indication for the treatment of breast cancer, and that the company believes it can obtain approval for this indication by early 2019.
The biosimilar was also approved in the European Union in February 2018, where it is also marketed under the brand name Herzuma. The product is not yet authorized in the United States, however, as Celltrion received a Complete Response Letter (CRL) for the drug in April 2018 from the FDA.
The CRL came after Celltrion had received the FDA’s Form 483 in 2017. Then, in February 2018, Celltrion received a warning letter from the agency related to its manufacturing processes. The drug maker has since resubmitted the product to the FDA for approval, and a regulatory decision is expected by the end of 2018.
However, despite the resubmission, Celltrion continues to face legal battles over the biosimilar in the United States. In January 2018, Celltrion and its partner Teva sought a declaratory judgment of noninfringement against Roche’s Genentech. In May 2018, Genentech was successful in its own request for the court to dismiss Celltrion and Teva’s petition.
Also in January, Genentech filed its own complaint against Celltrion and Teva, alleging that the partnership had infringed 40 patents. In June, Genentech moved to dismiss certain counterclaims, and in July, it filed a new complaint that alleged infringement of the same 40 patents covering Herceptin.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.